eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
stephen silberstein, md, director, jefferson university headache center.
.
.
when robert had to go on full medical disability in his early 50s after hurting himself at work, helen went back to work, this time in the oil industry.
.